Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › solid malignancies

Solid malignancies

Part of Cancer

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for solid malignancies

10 trials tracked for solid malignancies: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 10 citations.

10Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 1 Phase 1 8
  1. Phase 3 An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. Completed · 10 cited
  2. Phase 2 FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression Completed
  3. Phase 1 Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies. Completed
  4. Phase 1 Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies Completed
  5. Phase 1 Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase Completed
  6. Phase 1 Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma Completed
Show 4 more trials
  1. Phase 1 Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer Completed
  2. Phase 1 Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies Completed
  3. Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 Completed
  4. Phase 1 Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Solid malignancies: what the trials found

Clinical evidence for solid malignancies includes the use of MEDI4736 (Durvalumab) in a Phase 3 trial involving 867 participants 1.

Pharmacodynamic and safety evaluations were conducted for MLN0128 in two separate Phase 1 trials. In one cohort of 198 patients, MLN0128 demonstrated significant reductions in p4EBP1 (-64.1%), pAKT (-15.5%), and PS6 (-99.5%) from baseline 3. In a smaller cohort of 68 patients, the treatment was associated with a 100% incidence rate for various adverse event categories, including serious adverse events and those resulting in discontinuation, while 63% of participants experienced fatal adverse events within 30 days of the last dose 4.

Recent results — preliminary, needs further review

  • FGF401 was evaluated in a Phase 2 trial (N=172) but results are not yet confirmed 2.
  • AZD2014 showed high recovery rates (92.02%) by day 8 and specific radioactivity ratios in blood and saliva in a small cohort (N=4) 5.
  • In a Phase 1 trial of AZD2014 (N=172), significant reductions were observed in p4EBP1 (-21.7% to -78.8%) and pAKT (-62.9% to -82.7%) at 2 hours post-dose 8.
  • Ixabepilone was evaluated in a Phase 1 trial (N=35) where hematology results showed grades ranging from 5 to 10 10.

For the clinician treating this condition

  • MEDI4736 (Durvalumab) is established in Phase 3 clinical data for solid malignancies 1.
  • MLN0128 demonstrates potent inhibition of p4EBP1 and PS6, but is associated with high rates of serious adverse events and discontinuation in early-phase trials [3, 4].

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review discusses perioperative local anesthetics and regional anesthesia in cancer care
Drug Pipeline Sys. Review
Narrative review discusses perioperative local anesthetics and regional anesthesia in cancer care Local Anesthetics May Slow Cancer Spread
This narrative review examines the role of perioperative local anesthetics and regional anesthesia compared to opioids within comprehensive …
Using local anesthesia instead of just opioids during surgery might help stop cancer from spreading after the operation.
Frontiers Apr 24, 2026
Subcutaneous amivantamab shows shorter administration time and fewer infusion reactions in advanced solid tumors
Oncology Phase I
Subcutaneous amivantamab shows shorter administration time and fewer infusion reactions in advanced solid tumors Could a simple injection replace hours-long cancer infusions?
A phase Ib clinical trial in 158 patients with advanced solid malignancies evaluated subcutaneous amivantamab administration.
A new injection method for advanced cancer treatment cuts administration time to under 10 minutes and reduces severe side effects compared t…
Apr 6, 2026

Research across Cancer

Related studies from across the Cancer family.

T cell signaling and metabolic rewiring are critical for T cell engager efficacy in solid tumors
Diabetes & Endocrinology Sys. Review
T cell signaling and metabolic rewiring are critical for T cell engager efficacy in solid tumors New research explores how cell metabolism affects cancer treatments
This mini-review explores the roles of T cell signaling and metabolism in T cell engagers (TCEs) for solid tumors and hematologic malignanci…
Scientists are looking at how the energy and nutrients inside immune cells impact the success of new cancer therapies.
Frontiers Jul 23, 2026
IEN plus NACT shows greatest improvement in CD4+ counts among ranked strategies
Rheumatology Meta-analysis
IEN plus NACT shows greatest improvement in CD4+ counts among ranked strategies New research identifies ways to protect immune cells during cancer surgery
This network meta-analysis of 82 RCTs evaluates multimodal interventions to maintain T lymphocyte subsets in patients with solid tumors unde…
A new analysis shows that combining specific nutrition and therapies can help maintain vital immune cell levels for patients undergoing soli…
Frontiers Jul 19, 2026
KRAS G12C inhibitors improve progression-free survival with HR 0.62 in KRASG12C-mutated solid tumors
Allergy & Immunology Meta-analysis
KRAS G12C inhibitors improve progression-free survival with HR 0.62 in KRASG12C-mutated solid tumors New drugs show promise for patients with specific tumor mutations
This meta-analysis of 3 RCTs involving 949 patients evaluated KRAS G12C inhibitors for solid tumors. The analysis found a significant improv…
A new class of drugs shows promise in slowing the growth of certain solid tumors for patients with a specific genetic mutation.
Frontiers Jul 10, 2026
Synergistic Effects of Immune Checkpoint Inhibitors and Radiotherapy in Solid Tumor Management
Oncology Meta-analysis
Synergistic Effects of Immune Checkpoint Inhibitors and Radiotherapy in Solid Tumor Management Combining immune checkpoint inhibitors and radiotherapy improves survival outcomes
Meta-analysis data indicates that combining immune checkpoint inhibitors with radiotherapy significantly improves survival outcomes in solid…
New data shows that adding immune checkpoint inhibitors to radiation therapy can improve survival for patients with many types of solid tumo…
Jul 9, 2026
Next-generation engineered constructs aim to overcome immunosuppressive tumor microenvironments in refractory malignancies
Allergy & Immunology Sys. Review
Next-generation engineered constructs aim to overcome immunosuppressive tumor microenvironments in refractory malignancies New framework aims to improve treatment for solid tumors
This systematic review synthesizes clinical data regarding CAR-T cells and bispecific antibodies for solid tumors and refractory malignancie…
Doctors are looking at new ways to use CAR-T cells and bispecific antibodies earlier in the treatment of hard-to-treat cancers.
Frontiers Jun 30, 2026
Pseudoprogression in immune checkpoint inhibitor therapy is associated with modest tumor growth and early progression
Oncology Meta-analysis
Pseudoprogression in immune checkpoint inhibitor therapy is associated with modest tumor growth and early progression Immune Checkpoint Inhibitors May Cause Initial Tumor Growth in Cancer
This meta-analysis of retrospective data examines patients with solid tumors experiencing pseudoprogression during immune checkpoint inhibit…
A growing tumor during immunotherapy might actually be a sign that the treatment is working, not a sign that the cancer is spreading.
Jun 17, 2026
cGAS–STING activation correlates with improved survival and enhanced checkpoint blockade response in cancer
Oncology Sys. Review
cGAS–STING activation correlates with improved survival and enhanced checkpoint blockade response in cancer Activating a cancer-fighting immune pathway can help tumors shrink but too much may backfire
This narrative review synthesizes evidence on cGAS–STING pathway activation in cancer. The authors report that heightened activity correlate…
Turning on a specific immune pathway helps some cancer patients survive longer, yet overactivating it can cause the immune system to stop wo…
Frontiers Jun 3, 2026
T cell-based therapies show promise but face barriers in solid tumors
Oncology Sys. Review
T cell-based therapies show promise but face barriers in solid tumors CAR-T and TIL therapies face hurdles in treating solid tumors
This narrative review examines CAR-T, TIL, and TCE therapies for hematologic and solid malignancies. Key challenges include on-target/off-tu…
A review notes that CAR-T, TIL, and TCE therapies struggle with tumor microenvironments and manufacturing issues for solid cancers.
Frontiers Jun 2, 2026
Chemoimmunotherapy improves survival in solid tumors regardless of liver metastasis status
Gastroenterology Meta-analysis
Chemoimmunotherapy improves survival in solid tumors regardless of liver metastasis status Chemoimmunotherapy helps solid tumor patients, with or without liver metastases
This systematic review and meta-analysis evaluated 25915 patients with solid tumors receiving chemoimmunotherapy versus chemotherapy alone. …
For people with solid tumors, adding immunotherapy to chemo helps survival whether or not cancer has spread to the liver.
Jun 1, 2026
Cadonilimab plus chemotherapy improves objective response rate to 0.62 in solid tumor patients
Dermatology Meta-analysis
Cadonilimab plus chemotherapy improves objective response rate to 0.62 in solid tumor patients Meta-analysis shows cadonilimab plus chemo improves outcomes for solid tumors
This systematic review and meta-analysis evaluated cadonilimab in patients with solid tumors, including gastric cancer and cervical non-smal…
A meta-analysis of 1,359 patients found cadonilimab combined with chemotherapy improved response rates and survival for solid tumors includi…
Frontiers May 30, 2026
Review of BsAb-armed T cells for solid tumors and CAR-T and BsAb therapy
Oncology Sys. Review
Review of BsAb-armed T cells for solid tumors and CAR-T and BsAb therapy BsAb-armed T cells may help solid tumors fight back against cancer
This narrative review synthesizes evidence on BsAb-armed T cells (EATs) for solid tumors, comparing them to CAR-T and BsAb therapy. The auth…
New review suggests BsAb-armed T cells could improve tumor infiltration and reduce immune escape in solid tumors compared to standard CAR-T …
Frontiers May 27, 2026
Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
Allergy & Immunology Sys. Review
Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases Review of tarlatamab for solid tumors and small cell lung cancer
This review examines T cell engagers as a promising intervention for solid tumors, specifically small cell lung cancer. Current data suggest…
This review looks at tarlatamab, a T cell engager, for treating solid tumors and small cell lung cancer. It examines how these drugs work.
Frontiers May 27, 2026